For ICs encountering larger vessels, this stent provides significant stent expansion: up to 5.75 mm when deploying 3.5, 4.0, 4.5, and 5.0 mm stents.
Smaller stents—2.25, 2.5, 2.75, 3.0, 3.25 mm lengths—continue to expand to 3.75 mm.2
XIENCE Skypoint™ Stent exhibits excellent stent expansion that enables apposition for a wide range of vessel sizes.3 This helps ensure accurate stent placement and reduce the risk of geographic miss.
XIENCE Skypoint™ Stent exhibits excellent stent expansion that enables apposition for a wide range of vessel sizes while also delivering optimal patient outcomes.4 Treating long, tapered lesions is possible with a single stent.
Small Tapered Vessels: Similarly, choosing a smaller diameter XIENCE Skypoint™ Stent allows ICs to treat a small tapered vessel, from 2.25 mm to 3.75 mm.5
The XIENCE™ family of stents are built on the MULTI-LINK platform. Its 3 links per ring connect the peaks of one ring to the valleys of the adjacent ring. This prevents struts from either compressing together or stretching apart.
With the MULTI-LINK stent platform, XIENCE™ stents have better longitudinal strength, compared to other DES.6 This reduces the possibility of displacement or deformation for XIENCE Skypoint™ Stents.
* denotes statistically significant difference compared with XIENCE Skypoint™ Stent.
MAT-2105262 v2.0
INDICATIONS
Applies to XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems:
In addition, XIENCE Skypoint™ Stent System is indicated with reference vessel diameters of ≥ 2.25 mm to ≤ 5.25 mm.
CONTRAINDICATIONS
The XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems are contraindicated for use in:
WARNINGS
PRECAUTIONS
POTENTIAL ADVERSE EVENTS
Adverse events that may be associated with PCI treatment procedures and the use of a stent in native coronary arteries include, but are not limited to, the following:
The risks described below include the anticipated adverse events relevant for the cardiac population referenced in the contraindications, warnings and precaution sections of the everolimus labels / SmPCs and / or observed at incidences ≥ 10% in clinical trials with oral everolimus for different indications. Please refer to the drug SmPCs and labels for more detailed information and less frequent adverse events.
Applies only to XIENCE Sierra™ and XIENCE Alpine™
Live vaccines should be avoided and close contact with those that have had live vaccines should be avoided. Fetal harm can occur when administered to a pregnant woman. There may be other potential adverse events that are unforeseen at this time.
MAT-2100879 v5.0
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test